SHIN NIPPON BIOMEDICAL LABORATORIES (2395) FY2026 Q3

Quick View

Executive Summary

FY2026 Q3 (nine-month cumulative) results: Revenue 211.9B yen (YoY -4.7%), Operating Income 10.3B yen (YoY -45.7%), Ordinary Income 31.2B yen (YoY -24.6%), Net Income 22.3B yen (YoY -29.7%). Operating margin declined sharply to 4.8% from 8.5% in the prior year, driven by revenue recognition delays on large-scale studies, increased depreciation expenses from new facility investments, and 5.6B yen in business preparation costs at Satsuma Pharmaceuticals recorded in Q3. Non-operating income, particularly equity method investment income of 18.9B yen from Shin Nippon Science PPD and valuation gains on investment securities, partially offset the operating profit decline. Comprehensive income surged to 14.8B yen due to unrealized gains on investment securities. Total assets reached 1,130.8B yen with equity of 532.1B yen, reflecting a strengthened equity base despite significant increases in both investment securities (+74.3%) and short-term borrowings (+58.5%). The company revised full-year guidance downward, citing timing shifts in revenue recognition and additional TR business expenses.

Performance Drivers

Revenue declined 4.7% YoY to 211.9B yen, primarily due to revenue recognition delays on multiple large-scale preclinical studies that shifted to Q4 and beyond. The Non-Clinical CRO segment, which represents the core business, posted sales of 202.6B yen (-6.6% YoY) despite recording the highest-ever quarterly order intake of 100B yen in Q3 alone. Overseas orders grew significantly to 101.4B yen in the nine-month period, with the backlog reaching a record 177.6B yen. Cost of sales decreased 1.5% YoY to 139.7B yen, but SG&A expenses increased 0.7% to 61.9B yen, resulting in operating income of 10.3B yen (-45.7% YoY) and a compressed operating margin of 4.8%.

Non-operating income contributed 20.9B yen (prior year: 22.5B yen), comprising primarily 18.9B yen in equity method investment income from the Clinical CRO joint venture and other investment-related income. Non-operating expenses totaled 0.02B yen. The gap between operating income (10.3B yen) and ordinary income (31.2B yen) of 20.9B yen reflects significant dependence on non-operating income, particularly equity method gains and investment returns, to support overall profitability.

Extraordinary losses of 3.7B yen (prior year: 0.2B yen) include 3.0B yen in impairment losses and 0.6B yen in other losses, representing non-recurring factors. After tax expenses of 4.8B yen, net income attributable to owners reached 22.7B yen (including 0.4B yen from non-controlling interests). The ordinary-to-net income gap of 8.9B yen (28.5%) was driven by extraordinary impairment charges and tax burden.

This represents a "revenue down, profit down" pattern, where declining revenue combined with fixed cost burdens and strategic investments compressed margins, though order intake momentum suggests potential recovery ahead.

Segment Analysis

Non-Clinical CRO segment (Core Business): Revenue 202.6B yen (-6.6% YoY), Operating Income 40.9B yen (-20.5% YoY), Operating Margin 20.2%. This segment represents approximately 95.6% of total revenue and is the core profit driver. Despite the revenue decline due to timing shifts in large-scale study billing, order intake reached a record 257.9B yen (+13.7% YoY) in the nine-month period, with Q3 quarterly orders hitting an all-time high of 100B yen. Overseas orders from the US and Europe grew 36.6B yen YoY to 101.4B yen, and the overseas backlog expanded to 177.6B yen (+59.9B yen YoY). The segment secured new preferred provider agreements with a major domestic pharmaceutical company, bringing the total to four major Japanese pharma partners. Operating margin decline was attributed to (1) revenue timing shifts on large projects, (2) increased depreciation from new research facility and equipment investments, and (3) adjustments in gross profit calculations related to unrealized profit methodology changes.

Translational Research segment: Revenue 0.8B yen (+53.1% YoY), Operating Loss 28.6B yen (prior year loss: 15.9B yen). Satsuma Pharmaceuticals accounted for an operating loss of 19.4B yen, including 5.6B yen in business preparation expenses recorded in Q3. The remaining TR portfolio generated a 9.1B yen operating loss, improved from prior year through prioritization adjustments and expense controls on nasal delivery platform development programs.

Medipolis segment: Revenue 6.0B yen (+53.7% YoY), Operating Loss 0.2B yen (prior year loss: 0.02B yen). Growth driven by power generation and hotel operations.

US Real Estate segment: Revenue 1.4B yen, Operating Loss 0.9B yen.

Clinical CRO (equity method affiliate): Shin Nippon Science PPD contributed 18.9B yen in equity method income (-5.5B yen YoY), with headcount reaching 1,046 employees as of December 2025.

The core Non-Clinical CRO business drove both revenue composition and profit generation, though TR segment losses significantly offset consolidated operating income.

Key Metrics

Profitability: ROE 4.3% (implied prior year approximately 8-9%), Operating Margin 4.8% (prior year 8.5%), Net Profit Margin 10.5% (prior year 14.3%). The ROE decline reflects reduced profitability and lower asset turnover despite increased financial leverage. Operating margin compression of 3.7 percentage points signals significant operational headwinds from revenue timing and cost structure.

Efficiency: Total Asset Turnover 0.19x (annualized basis), Inventory Turnover 0.65x (DIO: 559 days), Receivables Turnover 4.17x (DSO: 88 days). Asset efficiency remains challenged by substantial inventory buildup and extended collection cycles, both contributing to working capital pressure.

Financial Health: Equity Ratio 47.1% (prior year 43.4%), Current Ratio 1.08x (prior year 1.18x). While the equity ratio improved modestly through retained earnings and valuation gains, the current ratio declined due to a 58.5% increase in short-term borrowings to 186.7B yen. Cash and deposits increased 28.1% to 154.1B yen, yielding a cash-to-short-term debt ratio of 0.83x, indicating insufficient liquid coverage of near-term obligations.

Leverage: Financial Leverage 2.13x (total assets/equity), Debt-to-Capital 43.5%, Interest Coverage 5.0x. Leverage has increased as short-term debt financing was deployed for strategic investments and working capital needs.

Cash Flow Analysis

Direct cash flow data was not provided in the XBRL filing. Based on balance sheet movements and profit structure, operating cash generation appears constrained by working capital absorption. The 33.8B yen increase in cash and deposits to 154.1B yen occurred alongside a 68.9B yen increase in short-term borrowings to 186.7B yen, suggesting that cash growth was funded primarily through external borrowing rather than operational cash generation.

Inventory increased to 157.6B yen with turnover days of 559, indicating significant capital tied up in work-in-progress preclinical studies. Trade receivables of 50.9B yen with 88-day collection cycles further stress working capital. The substantial increase in investment securities (+146.8B yen to 344.4B yen) represents strategic investing in biotech ecosystem companies under the SNBL Global Gateway initiative.

Capital expenditures are projected at 61.9B yen for the full year, with 42.7B yen incurred through Q3, primarily for the new EU NHP testing facility and advanced laboratory equipment. Depreciation is forecasted at 30.9B yen annually, with increased depreciation from recent facility completions contributing to operating margin compression.

Financing activities included dividend payments totaling approximately 20.8B yen based on a 50 yen per share annual dividend (20 yen interim + 30 yen year-end forecast) applied to 41.6M shares. Free cash flow adequacy cannot be definitively assessed without operating CF data, but the combination of short-term debt growth, elevated inventory/receivables, and high dividend payout ratio (91.7% of Q3 net income) suggests cash generation is under pressure.

Earnings Quality

Ordinary Income of 31.2B yen substantially exceeded Operating Income of 10.3B yen, with the 20.9B yen gap driven by non-operating income that includes 18.9B yen in equity method investment gains from Shin Nippon Science PPD and other investment-related returns. This represents a structural reliance on non-operating sources for profitability, with operating activities contributing only 33% of ordinary income.

Extraordinary losses of 3.7B yen included 3.0B yen in impairment charges (non-recurring) and 0.6B yen in other losses, impacting the ordinary-to-net income bridge.

Comprehensive income of 14.8B yen significantly exceeded net income of 22.7B yen, driven by 12.6B yen in other comprehensive income primarily from unrealized valuation gains on investment securities. These valuation gains are non-cash items subject to market volatility and do not represent recurring operating performance.

Accruals quality concern: While direct operating cash flow data is unavailable, the substantial increases in inventory (DIO 559 days) and receivables (DSO 88 days) combined with operating margin compression suggest that reported earnings are not fully converting to cash, indicating potential earnings quality issues from working capital absorption.

The business model increasingly depends on equity method gains and investment returns rather than core operating profitability, with the TR segment's 28.6B yen operating loss offsetting approximately 70% of the core Non-Clinical CRO segment's 40.9B yen operating income.

Guidance Update

Full-year guidance was revised downward: Revenue 306.9B yen (initial: 324.1B yen, -5.2%), Operating Income 26.0B yen (initial: 35.5B yen, -26.8%), Ordinary Income 53.5B yen (initial: 64.5B yen, -17.1%), Net Income 35.6B yen (initial: 46.5B yen, -23.4%). The revisions reflect two primary factors: (1) revenue recognition delays on large-scale preclinical studies shifting into the subsequent fiscal year, and (2) additional 12.4B yen in Satsuma business preparation expenses recorded in the second half. Management partially offset the impact through expense controls on other TR programs, limiting the operating income revision to 9.5B yen.

Progress rate through Q3: Revenue 69.0%, Operating Income 39.6%, Ordinary Income 58.3%, Net Income 63.8% of revised full-year guidance. Operating income progress of 39.6% significantly lags the standard 75% benchmark for Q3, indicating substantial Q4 profitability is required to achieve guidance. Revenue progress of 69.0% is also below the 75% benchmark but more reasonable given the billing timing dynamics. Management expects Q4 to capture deferred revenue from large studies and maintain the revised guidance targets.

The Non-Clinical CRO segment's record order intake of 257.9B yen in the nine-month period and record backlog of 177.6B yen provide visibility for future revenue recovery, though conversion timing remains a key execution risk. The 50 yen per share annual dividend (30 yen year-end) is maintained despite guidance cuts, representing a full-year payout ratio of approximately 58.5% based on revised net income guidance.

Shareholder Returns

The company declared an interim dividend of 20 yen per share and forecasts a year-end dividend of 30 yen per share, for a total annual dividend of 50 yen per share. Based on 41.6M shares outstanding, total dividend payments approximate 2.08B yen. Against Q3 cumulative net income of 22.7B yen, the implied nine-month payout ratio reaches 91.7%, which is elevated and raises sustainability concerns given the profit decline and working capital pressures.

On a full-year basis, the revised net income guidance of 35.6B yen implies a payout ratio of approximately 58.5% (2.08B yen / 35.6B yen), which is more moderate but still substantial relative to cash generation capacity. No share buyback program was disclosed, so total return ratio equals the dividend payout ratio.

Dividend sustainability assessment: The high nine-month payout ratio combined with cash-to-short-term debt coverage of only 0.83x and the 68.9B yen increase in short-term borrowings suggest that current dividend levels rely on external financing rather than internally generated cash flow. While the company's equity base has strengthened to 532.1B yen and cash holdings reached 154.1B yen, the operating cash conversion challenges (high inventory/receivables, compressed operating margins) warrant monitoring of dividend policy sustainability in the near term. Management's commitment to maintain the 50 yen annual dividend signals confidence in full-year guidance achievement and Q4 cash generation, but execution risk remains elevated.

Catalysts

Near-term:

• Q4 revenue recognition of large-scale preclinical studies deferred from Q1-Q3, critical for achieving revised full-year guidance with operating income requiring significant recovery from 39.6% progress rate
• Satsuma Pharmaceuticals Atzumi (intranasal DHE) partnering negotiations with major pharmaceutical companies, with transaction timing and structure directly impacting TR segment financial burden and potentially unlocking milestone payments
• Construction and qualification timeline for new EU NHP testing facility, with facility completion enabling capacity expansion to service the record 177.6B yen overseas backlog
• Refinancing or extension of 186.7B yen in short-term borrowings, with successful rollover critical to maintaining liquidity given 0.83x cash coverage ratio

Long-term:

• Overseas market penetration strategy leveraging preferred provider agreements with major pharmaceutical companies, with the target to expand beyond current four Japanese partners and secure additional large pharma relationships in the US and Europe
• SNBL Global Gateway ecosystem development through biotech investments (344.4B yen in investment securities), with portfolio monetization through exits or partnership facilitating returns to justify strategic capital allocation
• TR segment path to commercialization or strategic alternatives for nasal delivery platform assets beyond Satsuma, including potential out-licensing, partnerships, or portfolio rationalization to reduce operating loss of 28.6B yen
• Clinical CRO joint venture (Shin Nippon Science PPD) growth trajectory, with 1,046 headcount and 18.9B yen equity method income contribution positioning it as a stable profit source amid core business volatility
• Operating margin recovery initiatives in Non-Clinical CRO segment through pricing optimization, operating leverage from new facility utilization, and normalization of depreciation as a percentage of revenue post-investment cycle

Industry Benchmark (Reference - Proprietary Data)

Industry Position (Reference - Proprietary Analysis)

Profitability: ROE 4.3% significantly underperforms the IT & Telecom industry median of 8.2% (IQR: 3.5%-13.3%, n=99), placing the company in the lower quartile. Operating Margin 4.8% substantially trails the industry median of 8.0% (IQR: 3.4%-17.4%, n=99), though remains within the lower range. Net Profit Margin 10.5% exceeds the industry median of 5.6% (IQR: 2.2%-12.0%, n=99), ranking in the upper half, though this reflects non-operating income contributions rather than core operating strength.

Efficiency: Total Asset Turnover 0.19x (annualized) significantly lags the industry median of 0.68x (IQR: 0.52-0.95, n=99), indicating substantially lower asset productivity. Inventory Turnover Days of 559 is dramatically higher than the industry median of 13.17 days (IQR: 3.40-49.41, n=53), reflecting the long-cycle nature of preclinical testing contracts but also signaling potential working capital inefficiency. Receivables Turnover Days of 88 exceeds the industry median of 60.53 days (IQR: 45.96-79.94, n=89), indicating extended collection cycles.

Financial Health: Equity Ratio 47.1% underperforms the industry median of 59.5% (IQR: 43.7%-72.8%, n=99), placing leverage in the higher range. Current Ratio 1.08x is below the industry median of 2.13x (IQR: 1.56x-3.58x, n=92), signaling tighter liquidity compared to sector peers. Financial Leverage 2.13x exceeds the industry median of 1.66x (IQR: 1.36-2.14, n=99), near the upper quartile threshold.

Growth: Revenue Growth -4.7% YoY substantially underperforms the industry median of +10.5% (IQR: -1.6% to +20.5%, n=97), placing the company in contraction mode while the broader sector expands. Rule of 40 (Revenue Growth + Operating Margin) of 0.1% is significantly below the industry median of 0.20 (IQR: 0.02-0.34, n=97).

Note: Industry comparison based on IT & Telecom sector. Shin Nippon Biomedical Laboratories operates in pharmaceutical contract research, and direct CRO/pharmaceutical services sector benchmarks would provide more appropriate comparison. Against the provided IT & Telecom benchmarks, the company's long-cycle contract model, capital-intensive laboratory infrastructure, and strategic investment portfolio result in structural differences in turnover and margin profiles. The core Non-Clinical CRO segment's 20.2% operating margin substantially exceeds reported consolidated margins due to TR segment losses.

Source: Proprietary Analysis. Industry: IT & Telecom (N=99 companies), Comparison period: 2025-Q3, Data: Publicly available earnings reports.

Risk Factors

Revenue recognition timing risk (High likelihood, High impact): The deferral of multiple large-scale preclinical studies from Q3 to Q4 and beyond creates significant quarterly volatility and execution risk. With Q3 operating income progress at only 39.6% of full-year guidance, substantial Q4 revenue conversion is required. The long-duration, project-based revenue model inherent in preclinical CRO services means that client-driven protocol changes, regulatory delays, or study extensions can materially impact billing milestones. The record 177.6B yen overseas backlog provides medium-term visibility but near-term conversion uncertainty persists. Quantified impact: 9.5B yen operating income revision in current period.

Refinancing and liquidity risk (High likelihood, High impact): Short-term borrowings increased 68.9B yen to 186.7B yen while cash coverage reached only 0.83x, creating a 31B yen liquidity shortfall if all short-term debt matured simultaneously. The 45.5% short-term debt ratio and current ratio of 1.08x indicate constrained near-term financial flexibility. With operating cash generation under pressure from working capital absorption (559-day inventory turns, 88-day receivables) and a 91.7% nine-month dividend payout ratio, the company depends on credit facility renewals and additional financing to fund operations and strategic investments. Rising interest rates or credit tightening could materially increase financing costs (current interest coverage 5.0x provides moderate buffer) or restrict access to capital.

TR segment investment return and cash burn risk (Medium likelihood, High impact): The TR segment generated a 28.6B yen operating loss through Q3, with Satsuma Pharmaceuticals contributing 19.4B yen in losses including 5.6B yen in Q3 business preparation costs. Full-year Satsuma costs are projected at 12.4B yen in H2. Satsuma's intranasal migraine therapy (Atzumi) partnering negotiations face headwinds from negative perceptions of existing DHE nasal products and biotech market bifurcation limiting licensing opportunities with mid-tier partners. Extended partnering timelines or unfavorable deal economics would prolong cash consumption and potentially require asset impairments (3.0B yen impairment already recorded in Q3). Investment securities increased 146.8B yen to 344.4B yen under the Global Gateway strategy, exposing the company to portfolio company performance risk, mark-to-market volatility (12.6B yen unrealized gains in Q3 other comprehensive income could reverse), and illiquidity in private biotech holdings.

Key Takeaways from Earnings

Core business momentum diverges from near-term financial performance: The Non-Clinical CRO segment achieved record quarterly order intake of 100B yen in Q3 and accumulated a record overseas backlog of 177.6B yen (+59.9B yen YoY), with overseas orders growing 36.6B yen YoY despite a challenging biotech funding environment. Four preferred provider agreements with major Japanese pharmaceutical companies and 85% repeat customer rate among overseas clients demonstrate competitive positioning. However, large-scale study revenue timing shifts and strategic investment cycle costs (new facilities, TR segment losses) have compressed near-term profitability, creating a disconnect between operational momentum and reported financial results. The 4.8% consolidated operating margin significantly understates the core CRO business's 20.2% segment margin due to 28.6B yen in TR losses. Successful Q4 revenue conversion and sustained order intake will be critical to validate the growth trajectory implied by backlog metrics.

Capital allocation strategy introduces structural volatility and return uncertainty: Management has deployed substantial capital into two non-core areas: (1) 344.4B yen in investment securities (+146.8B yen YoY) for biotech ecosystem investments, and (2) ongoing TR segment development with 28.6B yen in nine-month operating losses. This strategy has shifted the earnings profile from stable CRO operations to a hybrid model dependent on equity method gains (18.9B yen from Clinical CRO JV), investment valuations (12.6B yen unrealized gains in Q3), and eventual TR commercialization. While comprehensive income of 14.8B yen reflects mark-to-market gains, operating income of 10.3B yen highlights limited self-sustaining profitability. The 186.7B yen in short-term borrowings and 58.5% full-year dividend payout ratio indicate that current returns from strategic investments do not yet fund capital requirements, creating reliance on external financing and valuation-driven gains rather than cash-generative business economics.

Working capital and cash conversion require operational improvement to support growth: Inventory days of 559 and receivables days of 88 have absorbed significant capital, with these metrics substantially exceeding industry norms even accounting for long-cycle CRO contracts. The combination of (1) working capital pressure, (2) elevated capex cycle (61.9B yen full-year forecast), (3) high dividend payout (91.7% of nine-month earnings), and (4) TR segment cash consumption has necessitated a 68.9B yen increase in short-term debt. The 0.83x cash-to-short-term debt ratio and 1.08x current ratio signal that liquidity management is critical. Operational improvements in project milestone billing, collections acceleration, and inventory efficiency would enhance self-funding capacity and reduce refinancing risk as the company scales to service the record backlog and new facility capacity.

---

This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.

---

AI Analysis (Earnings Presentation)

AI analysis of PDF earnings presentation

Summary

Materials from the Q3 FY2026 (fiscal year ending March 2026) earnings briefing of Shin Nippon Biomedical Laboratories, Ltd. Sales 211.9億円 (YoY -4.7%), operating profit 10.2億円 (YoY -46.1%), ordinary profit 31.1億円 (YoY -24.7%). Orders in the nonclinical CRO business reached 100億円 in Q3, a record high on a quarterly basis, and rose 13.7% YoY on a cumulative basis through Q3, progressing steadily. Meanwhile, revenue recognition for several large studies shifted to Q4 and beyond, and Q3 expenses at Satsuma (5.6億円) led to results falling short of plan. Orders from customers in Europe and the U.S. have expanded robustly with a 4-year CAGR of 27.0%. As a strategic investment, the company decided to establish the world-class NHP (non-human primate) experimental facility “EU Experimental Building” and is building out capabilities to accommodate growing overseas orders in the nonclinical business. Full-year guidance was revised downward, mainly due to second-half expenses at Satsuma (12.4億円) and timing deferrals in revenue recognition in the nonclinical CRO business. Partnering negotiations for the intranasal migraine therapy “AtzumiTM” are ongoing. At the J.P. Morgan Healthcare Conference in January, the company hosted a reception connecting Japanese and U.S. investors with biotech companies, accelerating efforts to build a drug discovery ecosystem.

Key Highlights

Q3 orders of 100億円 in the nonclinical CRO business set a record high on a quarterly basis. Q3-end order backlog from Europe and the U.S. customers was 177.6億円 (YoY +36.7%, 4-year CAGR 36.7%). New preferred provider agreements concluded with major pharmaceutical companies in Japan and overseas (domestic framework to expand to 4 companies). Decision to establish the world-class NHP experimental facility “EU Experimental Building,” entering a strategic investment phase (capital expenditures 61.9億円). Hosted a reception at the J.P. Morgan Healthcare Conference 2026 to advance the construction of a drug discovery ecosystem (approximately 200 participants).

Business Outlook

Full-year outlook revised to sales of 306.9億円 (YoY -5.3%) and operating profit of 26.0億円 (YoY -12.8%). Orders in the nonclinical business remain solid, with strong momentum from Europe and the U.S. The company will continue activities aimed at new contracts in Q4, targeting full-year orders of 352億円. While the timing shift of revenue recognition for large studies is a headwind this fiscal year, the accumulation of backlog is strengthening the growth foundation for the next fiscal year and beyond.

Management Guidance

The primary factors behind the downward revision to full-year results are the revenue timing deferrals into next fiscal year due to the scale-up of nonclinical studies and the recognition of second-half expenses (12.4億円) associated with ongoing partnering negotiations for Satsuma. Meanwhile, in the TR business excluding Satsuma, expense control of 6.7億円 limited the downward revision in operating profit to -9.5億円. The company will continue partnering negotiations to maximize the product value of AtzumiTM. To drive sustainable growth, strategic investments are being accelerated, and the establishment of the EU Experimental Building will create a world-leading experimental platform.

Strategic Initiatives

Establish the world-class NHP experimental facility “EU Experimental Building” to build capabilities to accommodate increasing orders from Europe and the U.S. in the nonclinical business. Expand preferred provider agreements with major pharmaceutical companies in Japan and overseas (4 domestic companies, multiple overseas companies). Strengthen the SGG business to build a drug discovery ecosystem (including hosting a reception at the J.P. Morgan Healthcare Conference). Enhance contract service offerings for MPS (Microphysiological Systems) and expand new service menus that complement animal studies. Acquired exclusive domestic distribution rights for the self-blood collection device “Tasso Mini” and established SNBL Tasso (sales start in December 2025).

Reference Assumptions

• USD/JPY: 155円/ドル（修正予想の前提レート）
• Other: Revenue timing deferrals into next fiscal year due to the scale-up of nonclinical studies; recognition of 12.4億円 in second-half expenses at Satsuma; equity-method income from 新日本科学PPD is 18.9億円 for January–September actuals, with a full-year forecast of 24.7億円

Disclosed Risks

Risk of earnings volatility due to revenue recognition timing deferrals associated with the scale-up of nonclinical studies. Risk of increased expenses due to delays in Satsuma’s partnering negotiations (polarization of the U.S. biotech market, challenges in dispelling perceptions of marketed DHE formulations). Risk that increased depreciation from intensified investment in experimental equipment and facilities will compress operating profit. Foreign exchange risk (assumed rate 155円/ドル; actual Q1: 143.72円, Q2: 148.35円, Q3: 155.75円 with continued yen depreciation). Risk of declining equity-method income from 新日本科学PPD (Q3 cumulative 18.9億円, down 5.5億円 YoY).

Q&A Insights

The Q&A section is not included in the materials

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was weak at the operating level, with lower CRO activity and a substantial margin contraction, while non-operating affiliate income preserved a double-digit net margin. Revenue declined 4.7% YoY to ¥21.20bn. Operating income fell 45.7% to ¥1.03bn, materially underperforming the top-line decline. The operating margin compressed by 366bp to 4.8% from 8.5% in the prior-year period. Gross margin declined by 108bp to 51.5%, indicating some deterioration in project or service-level profitability. SG&A expenses were broadly flat, down only 0.1% YoY, and therefore did not adjust sufficiently to offset the revenue decline. Ordinary income fell by a less severe 24.6% to ¥3.12bn because non-operating income totaled ¥2.31bn. Equity-method earnings of ¥1.97bn were the principal contributor to non-operating income and exceeded reported operating income. Net income attributable to owners decreased 29.2% to ¥2.27bn, while the net profit margin remained 10.7%. A ¥0.38bn extraordinary loss, mainly a ¥0.37bn fixed-asset disposal loss, further reduced profit before tax. Total comprehensive income rose to ¥14.84bn, primarily reflecting a ¥14.73bn positive valuation difference on securities, which substantially increased equity but is not operating cash earnings. The core CRO business remained profitable but saw both revenue and segment-profit declines. Translational research and US real estate remained loss-making, while Medipolis narrowed its loss despite low absolute earnings contribution. The Q3 cumulative operating-income progress rate is only 39.5% of full-year guidance, well below the standard 75% pace, implying a highly back-end-loaded plan. Revenue progress is 69.0%, also below the standard 75% pace, although the shortfall is less pronounced than for operating profit. The investment case therefore hinges on a sharp Q4 operating recovery, sustained affiliate earnings, and improved conversion of a large inventory position into revenue and cash.

Profitability Analysis

The provided DuPont analysis shows ROE of 5.7%, decomposed into a 10.7% net profit margin, 0.250x asset turnover, and 2.13x financial leverage. The low-return outcome is principally explained by weak asset turnover and a sub-5% EBIT margin rather than by inadequate accounting net margin. Financial leverage supports ROE, but it also increases sensitivity to refinancing conditions and interest costs. Net margin is flattered by non-operating income: non-operating income of ¥2.31bn represented 10.9% of revenue, with ¥1.97bn of equity-method earnings accounting for the majority. Consequently, the 10.7% net margin is not representative of the 4.8% operating profitability of the consolidated operating businesses. The operating margin fell 366bp YoY to 4.8%, triggering the low-operating-efficiency alert and placing profitability below the 5% concern threshold. Gross margin declined 108bp to 51.5%, while nearly unchanged SG&A against a 4.7% revenue decline created negative operating leverage. The core CRO segment generated ¥20.22bn in external revenue, down 6.5% YoY, and segment profit of ¥4.09bn, down 20.5%; its segment margin contracted to 20.2% from 23.8%. Translational research revenue grew 45.7% to ¥0.07bn but its segment loss widened to ¥2.86bn from ¥2.76bn. Medipolis revenue increased 66.2% to ¥0.53bn and its loss narrowed materially to ¥0.02bn from ¥0.28bn. US real estate contributed ¥0.14bn of revenue but reported a ¥0.09bn segment loss. Other businesses recorded revenue of ¥0.24bn, down 5.6%, and segment profit of ¥0.02bn, down 54.3%. Interest coverage of 5.02x is at the lower edge of a strong-credit benchmark, while the 2.678x interest-burden ratio reflects non-operating income exceeding the gap between EBIT and pre-tax income rather than low debt dependence. The 1.4% ROIC quality alert is a material capital-efficiency concern, particularly given the large balance of property assets and investment securities. Improvement requires a restoration of CRO utilization and margin, tighter cost discipline, and better returns from capital deployed outside the core CRO franchise.

Growth Assessment

Revenue contraction was concentrated in the core CRO business, which remains the dominant earnings engine and therefore determines the near-term growth trajectory. CRO external revenue fell ¥1.40bn YoY to ¥20.22bn, more than offsetting growth in Medipolis, translational research, and the addition of US real estate revenue. The decline in CRO segment profit of ¥1.06bn was more severe than the revenue decline, indicating unfavorable operating leverage and/or weaker project mix. Medipolis showed encouraging growth and a substantial reduction in losses, but its ¥0.53bn revenue base remains too small to offset weakness in CRO. Translational research revenue growth was positive but remains immaterial relative to its ¥2.86bn segment loss. Full-year guidance calls for revenue of ¥30.70bn, down 5.2% YoY, operating income of ¥2.60bn, down 12.8%, ordinary income of ¥5.35bn, down 17.0%, and EPS of ¥85.53. Q3 cumulative revenue represents 69.0% of the full-year target versus a standard 75% seasonal progress rate. Cumulative operating income represents only 39.5% of guidance, a 35.5 percentage-point shortfall to the standard pace. Ordinary-income progress is 58.3% and attributable-profit progress is 63.7%, both also behind a standard 75% pace but supported by non-operating earnings. Achieving guidance requires approximately ¥9.50bn of Q4 revenue and ¥1.57bn of Q4 operating income, equating to an implied Q4 operating margin of about 16.5%. This implied margin is far above the 4.8% Q3 cumulative margin and makes the forecast highly dependent on project timing, utilization recovery, or large seasonal profit recognition. Profit quality would improve if operating income, rather than equity-method income, becomes the primary driver of the forecast delivery.

Financial Health

Liquidity is positive but tight for the group’s debt structure. The current ratio is 1.08x, above 1.0x and therefore not an immediate current-liability coverage breach, but materially below the 1.5x healthy benchmark. The quick ratio is 0.63x, indicating that current-liability coverage depends meaningfully on inventories and other non-quick current assets. Working capital is positive at ¥2.84bn, but the balance is modest relative to ¥34.98bn of current liabilities. Short-term loans increased 58.5% YoY to ¥18.67bn, while long-term loans were broadly stable at ¥22.37bn, bringing total interest-bearing debt to ¥41.04bn. The 45.5% short-term debt ratio triggers the refinancing-risk alert because a large proportion of borrowings requires frequent rollover or refinancing. Cash and deposits rose 28.1% to ¥15.41bn, but cash covers only 0.83x short-term loans, leaving reliance on operating cash conversion, asset liquidity, and credit-market access. Debt-to-equity is 1.13x, above the conservative 1.0x benchmark but below the 2.0x aggressive-leverage warning level. Debt-to-capital is 43.5%, moderately above the 40% investment-grade reference point but well below the 60% concern threshold. Investment securities increased 74.3% YoY to ¥34.44bn and account for 30.5% of total assets; the increase coincided with a ¥14.73bn valuation gain recognized in OCI. This securities exposure supported total equity growth to ¥53.21bn from ¥40.09bn, but also introduces market-value volatility into book value and capital ratios. Property, plant and equipment of ¥36.08bn represents 31.9% of assets, underscoring a capital-intensive balance sheet. Goodwill is limited at ¥1.76bn, equal to 3.3% of equity and 1.6% of assets, so balance-sheet dependence on acquisition value retention is low. Lease obligations of ¥0.48bn are an additional fixed contractual obligation, though small relative to interest-bearing debt.

Notable B/S Changes

Investment securities: +¥14.68bn (+74.3%) to ¥34.44bn, representing 30.5% of assets; the associated ¥14.73bn securities valuation gain in OCI materially lifted equity but increases exposure to market-price volatility. Short-term loans: +¥6.89bn (+58.5%) to ¥18.67bn; this increased refinancing dependence and lifted the short-term debt ratio to 45.5%. Cash and deposits: +¥3.38bn (+28.1%) to ¥15.41bn; liquidity improved in absolute terms but remains below short-term borrowings, with cash/short-term debt of 0.83x. Accounts payable: +¥0.30bn (+64.7%) to ¥0.76bn; the absolute amount is small, but the rise provides limited supplier-financing support relative to the inventory balance. Total equity: +¥13.12bn (+32.7%) to ¥53.21bn; the increase was driven predominantly by accumulated valuation and translation adjustments, including securities valuation gains, rather than retained operating earnings. Inventories: +¥3.14bn (+24.9%) to ¥15.76bn; combined with 419 inventory days, the build-up heightens working-capital, turnover, and potential valuation risk.

Cash Flow Quality

The combination of a 465-day cash conversion cycle, 66-day DSO, and 419-day DIO indicates structurally heavy working-capital absorption risk. DSO exceeds the 60-day alert threshold, increasing exposure to collection timing and customer-credit risk. Inventory days of 419 are exceptionally high relative to the 90-day benchmark and require close monitoring of inventory composition, turnover, and potential valuation risk. Inventories increased 24.9% YoY to ¥15.76bn and now represent 13.9% of total assets. The long cash conversion cycle is particularly important because cash of ¥15.41bn is below short-term loans of ¥18.67bn. Advances received of ¥12.42bn provide an important source of operating funding and partly mitigate the working-capital burden. However, the increase in inventories alongside lower revenue indicates that inventory monetization must improve to reduce funding needs. Reported net income includes substantial non-operating equity-method earnings of ¥1.97bn and large unrealized securities valuation gains within comprehensive income; these items should be distinguished from cash earnings. The ¥14.73bn OCI valuation gain strengthened equity but does not by itself enhance debt-service capacity. The fixed-asset disposal loss of ¥0.37bn is non-recurring and reduced reported earnings, but it does not alter the more important operating-profit weakness. Cash-flow quality should be assessed primarily through future operating cash generation, inventory conversion, receivable collections, and the degree to which affiliate earnings translate into distributions or other liquidity.

Dividend Sustainability

The company paid an interim dividend of ¥20 per share and guides for a full-year dividend of ¥50 per share. Based on forecast EPS of ¥85.53, the indicated full-year dividend payout ratio is approximately 58.5%, within the stated sub-60% sustainability benchmark but leaving limited headroom if earnings underperform. The Q2 dividend of ¥20 represented a calculated 36.7% payout ratio against the referenced interim earnings base. The planned year-end dividend implied by guidance is ¥30 per share. The payout profile appears supportable on forecast earnings, but forecast attainment is important because operating-income progress is only 39.5% at Q3. Dividend capacity is also influenced by the elevated inventory cycle, reliance on short-term debt, and need to refinance ¥18.67bn of short-term loans. The substantial OCI-driven increase in equity should not be treated as a substitute for recurring distributable cash generation. No share buyback is reflected in the provided share data, so the analysis refers to the dividend payout ratio rather than a total return ratio.

Risk Assessment

Business risks include Core CRO risk: CRO revenue declined 6.5% YoY and segment profit declined 20.5%, with segment margin falling 361bp to 20.2%. As the largest and only materially profitable operating segment, further project delays, lower utilization, or adverse study mix would have an outsized effect on group earnings., Development-business losses: Translational research generated only ¥0.07bn of revenue but a ¥2.86bn loss, while US real estate recorded a ¥0.09bn loss. Continued losses could consume returns generated by the CRO business., Industry-specific CRO risk: Demand is sensitive to pharmaceutical and biotechnology clients’ R&D budgets, clinical-development pipelines, outsourcing decisions, trial timing, and regulatory requirements. Project postponements can quickly lower facility and personnel utilization., Investment-income concentration: Equity-method earnings of ¥1.97bn exceeded operating income of ¥1.03bn. Affiliate performance volatility can materially affect ordinary and net income even if consolidated operations remain weak., Securities-market risk: Investment securities equal 30.5% of assets, and OCI includes a ¥14.73bn valuation gain. Market-price declines could reverse a meaningful portion of the recent increase in equity..

Financial risks include Refinancing risk is elevated because short-term loans increased 58.5% YoY to ¥18.67bn and comprise 45.5% of interest-bearing debt. Cash covers only 0.83x of short-term loans, requiring continued access to funding markets and/or operating liquidity., Liquidity is modest: the current ratio is 1.08x and the quick ratio is 0.63x. The latter indicates material dependence on inventory realization and other non-quick assets to meet current obligations., Capital efficiency is weak, with ROIC of 1.4% and provided ROE of 5.7%. Returns are below relevant benchmarks despite leverage of 2.13x., Interest coverage of 5.02x is adequate but has limited cushion if operating income declines further or funding costs rise..

Key concerns include The 4.8% EBIT margin is below the 5% quality-alert threshold and declined 366bp YoY; this is the most immediate operating concern., The 465-day cash conversion cycle, driven by 419-day inventory days and 66-day receivable days, is a material working-capital and cash-generation concern., Full-year operating-income guidance requires an implied Q4 operating margin of approximately 16.5%, creating significant execution risk., Comprehensive income of ¥14.84bn is largely driven by unrealized securities valuation gains rather than recurring operating profit, so book-value growth should not be equated with earnings recovery..

Investment Implications

Key takeaways include Operating earnings weakened materially: Q3 cumulative revenue fell 4.7%, operating income fell 45.7%, and operating margin fell to 4.8%., The CRO operation is the core business, but its revenue and segment profit both declined, making a CRO utilization and margin recovery central to future performance., Ordinary and net income are materially supported by ¥1.97bn of equity-method earnings, reducing the comparability of headline net margin with operating profitability., Balance-sheet equity strengthened substantially through securities valuation gains, while increased short-term borrowing and weak working-capital efficiency raise liquidity-management importance., The low goodwill burden limits M&A-related impairment risk, but returns on the large asset base remain weak..

Metrics to watch include CRO revenue growth, segment margin, project starts, and utilization trends, Q4 operating-income delivery relative to the ¥2.60bn full-year target, Equity-method earnings and the underlying performance of affiliates, Inventory balance, DIO, receivable days, and cash conversion cycle, Short-term debt rollover, cash-to-short-term-debt coverage, interest expense, and interest coverage, Fair-value movements in ¥34.44bn of investment securities and their effect on OCI and equity, Loss trajectory and capital requirements in translational research, Medipolis, and US real estate.

Regarding relative positioning, Relative to profitability and liquidity benchmarks, the company has a strong gross margin but weak operating conversion, low capital efficiency, and below-healthy quick liquidity. Its balance sheet has limited goodwill risk and meaningful securities value, but the debt maturity profile and unusually long cash conversion cycle make it more financially sensitive than a cash-generative, asset-light CRO peer.